Inhaler assessment in COPD patients

Chronic obstructive pulmonary disease (COPD) is an incurable disease that affects 4.2% of Canadians 35 years of age and older.1-3 Pharmacotherapy for COPD is prescribed to achieve 2 main goals of therapy: symptomatic improvement/quality of life and reduction in frequency and severity of exacerbations.4 Administration of medication via inhalation is the preferred route of drug delivery for respiratory disease treatment.3,4 The inhalation route allows for medications to be delivered directly to the intended site of action with minimal systemic absorption, resulting in enhanced clinical benefit and reduced risk of systemic adverse effects.3,5